April 12 (Reuters) - Galapagos NV:
* GALAPAGOS ANNOUNCES ISABELA PHASE 3 PROGRAM IN IPF
* ANNOUNCES DESIGN OF A WORLDWIDE PHASE 3 PROGRAM TO EVALUATE GLPG1690 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
* GLOBAL PHASE 3 PROGRAM IS EXPECTED TO CONSIST OF TWO IDENTICALLY DESIGNED TRIALS, ISABELA 1 AND ISABELA 2
* PHASE 3 PROGRAM IS EXPECTED TO START DOSING IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.